| Income Statement | 2025-09-30 | 2025-06-30 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
| Revenue | 1,571 | 2,170 | 9,018 | 4,475 |
| Cost of revenues | 111 | 154 | 259 | 234 |
| Research and development (includes x and 9,911 of share-based compensation expense for the three months ended september 30, 2025 and 2024 and x and 20,443 for the six months ended september 30, 2025 and 2024, respectively) | 164,568 | 152,919 | 141,595 | 143,073 |
| Acquired in-process research and development | - | - | 0 | 0 |
| General and administrative (includes x and 59,443 of share-based compensation expense for the three months ended september 30, 2025 and 2024 and x and 96,284 for the six months ended september 30, 2025 and 2024, respectively) | 143,125 | 134,019 | 141,545 | 202,881 |
| Total operating expenses | 307,804 | 287,092 | 283,399 | 346,188 |
| Gain on sale of telavant net assets | 0 | 0 | 0 | 0 |
| Loss from operations | -306,233 | -284,922 | -274,381 | -341,713 |
| Change in fair value of investments | 128,501 | -19,125 | -21,314 | 48,375 |
| Change in fair value of liability instruments | -20,959 | -2,329 | 2,147 | 635 |
| Gain on deconsolidation of subsidiaries | - | - | 0 | 0 |
| Interest income | 45,341 | 48,322 | 61,851 | 69,773 |
| Other expense, net | -5,694 | -11,208 | -2,816 | -1,453 |
| Loss from continuing operations before income taxes | -159,044 | -269,262 | -234,513 | -224,383 |
| Income tax expense | 6,995 | 4,649 | -25,568 | 12,458 |
| Loss from continuing operations, net of tax | -166,039 | -273,911 | -208,945 | -236,841 |
| Revenue, net | - | - | 3,508 | 24,787 |
| Cost of revenues | - | - | 1,695 | 6,656 |
| Research and development | - | - | 3,210 | 8,396 |
| Selling, general and administrative | - | - | 25,750 | 45,503 |
| Total operating expenses | - | - | 30,655 | 60,555 |
| Loss from operations | - | - | -27,147 | -35,768 |
| Gain on sale of subsidiary interests | - | - | 376,506 | - |
| Change in fair value of debt | - | - | -5,330 | -16,700 |
| Interest expense | - | - | 10,688 | 6,469 |
| Other expense (income), net | - | - | -7,183 | 16,658 |
| Income (loss) from discontinued operations before income taxes | - | - | 326,158 | -42,279 |
| Income tax (benefit) expense | - | - | -862 | 804 |
| (loss) income from discontinued operations, net of tax | 0 | 0 | 327,020 | -43,083 |
| Net loss | -166,039 | -273,911 | 118,075 | -279,924 |
| Net loss attributable to noncontrolling interests | -52,520 | -50,556 | -51,306 | -49,740 |
| Net loss attributable to roivant sciences ltd | -113,519 | -223,355 | 169,381 | -230,184 |
| Basic (in shares) | 680,947,866 | 680,286,922 | 722,716,168 | 735,470,796 |
| Basic net loss per common share (in dollars per share) | -0.17 | -0.33 | 0.23 | -0.31 |
| Diluted (in shares) | 680,947,866 | 680,286,922 | 722,716,168 | 735,470,796 |
| Diluted net loss per common share (in dollars per share) | -0.17 | -0.33 | 0.23 | -0.31 |
Roivant Sciences Ltd. (ROIV)
Roivant Sciences Ltd. (ROIV)